Arcutis Biotherapeutics, Inc.
ARQT
Rang in Aktien
#4365
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to... Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
Aktienkurs
$28.54
Zuletzt synchronisiert: 2026-10-16
Marktkapitalisierung
$3.59B
Veränderung (1 Tag)
-1.94%
Veränderung (1 Jahr)
36.66%
Land
US
Handel Arcutis Biotherapeutics, Inc. (ARQT)
Kategorie
Healthcare
EPS für Arcutis Biotherapeutics, Inc. (ARQT)
EPS zum June 2026 TTM: $0.22
Laut den aktuellen Finanzberichten und dem Aktienkurs von Arcutis Biotherapeutics, Inc. beträgt das aktuelle EPS des Unternehmens (TTM) $0.22. Am Ende des Jahres 2023 betrug das EPS $-3.78 ein Rückgang im Vergleich zu dem EPS von 2022, das $-5.66 betrug.
EPS-Verlauf von Arcutis Biotherapeutics, Inc. von 2017 bis 2026
EPS am Ende jedes Jahres
| Jahr | EPS | ändert |
|---|---|---|
| 2026 (TTM) | $0.22 | -118.97% |
| 2024 | $-1.16 | -69.31% |
| 2023 | $-3.78 | -33.22% |
| 2022 | $-5.66 | 35.73% |
| 2021 | $-4.17 | 9.74% |
| 2020 | $-3.80 | 245.45% |
| 2019 | $-1.10 | 107.55% |
| 2018 | $-0.53 | -88.75% |
| 2017 | $-4.71 | 0.00% |
EPS für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | EPS | EPS-Differenz | Land |
|---|---|---|---|
| $17.32 | 7,772.73% |
US
|
|
| $-7.98 | -3,727.27% |
US
|
|
| $-5.29 | -2,504.55% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | 12,509.09% |
NL
|
